INVESTOR ALERT: Monteverde & Associates PC Invites Roche Holding AG Shareholders with Significant Losses to Contact the Firm Immediately - RHHBY

NEW YORK, June 29, 2017

The lawsuit is based on whether Roche Holding and its executives violated federal securities law by misleading investors by making false and/or misleading statements regarding the Company's business, operational and compliance policies specifically that the combination of the Company's breast cancer drug, Perjeta, and its older treatment, Herceptin, is only marginally more effective than Herceptin alone in preventing breast cancer, and has a higher rate of side effects. When this information reached the public, shares of Roche Holding lowered in value materially, causing investors harm according to the Complaint.

Mr. Monteverde would like to personally discuss with you how to potentially recover your monetary losses, if incurred during the Class Period.

If you wish to serve as lead plaintiff, you must move the Court no later than August 7, 2017. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

Click here for more information: http://monteverdelaw.com/securities/.  It is free and there is no cost or obligation to you.

Monteverde & Associates PC is a boutique class action securities and consumer litigation law firm committed that has recovered millions of dollars and is committed to protecting shareholders and consumers from corporate wrongdoing.  Monteverde & Associates PC lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions, whereby they protect investors by recovering money and remedying corporate misconduct.